Hematology

Question 1

Brukinsa: generic name?

Answer 1

Zanubrutinib

Question 2

Zanubrutinib: brand name?

Answer 2

Brukinsa

Question 3

Brukinsa: indication(s)?

Answer 3

1. Chronic Lymphocytic Leukemia (CLL) / Small Lymphocytic Leukemia (SLL)
2. Waldenstrom’s Macroglobulinemia (WM)
3. Mantle-Cell Lymphoma (MCL), previously treated
4. Marginal-Zone Lymphoma (MZL), previously treated
5. Follicular Lymphoma (FL), previously treated

Question 4

Brukinsa: mechanism of action?

Answer 4

BTK-inhibitor.
BTK is a signalling molecule on B-cell antigen receptor, necessary for B-cell proliferation.

Question 5

Brukinsa: administration?

Answer 5

PO, 160 mg (2 tabs) twice daily, or 320 mg (4 tabs) once daily.

Question 6

Brukinsa: partner?

Answer 6

BeiGene

Question 7

Brukinsa: adverse effects?

Answer 7

1. Hemorrhage
2. Infections (mostly URTI)
3. Neutropenia / Thrombocytopenia
4. Arrhythmias

Question 8

Blincyto: generic name?

Answer 8

Blinatumomab

Question 9

Blinatumomab: brand name?

Answer 9

Blincyto

Question 10

Blincyto: indication(s)?

Answer 10

CD-19 B-cell Precursor Acute Lymphoblastic Leukemia (All), with either Minimal Residual Disease (MRD) or refractory/relapsed disease

Question 11

Blincyto: partner?

Answer 11

Amgen

Question 12

Blincyto: administration?

Answer 12

IV, various protocols

Question 13

Vorasidenib: Indication(s)?

Answer 13

IDH-mutant low-grade glioma

Question 14

Vorasidenib: efficiency?

Answer 14

Progression-free survival 27.7 months vs 11.1 months for placebo (INDIGO Trial, NEJM 2023)

Question 15

Vorasidenib: partner?

Answer 15

Servier